Drug Patents owned by Biocryst

1. List of Orladeyo drug patents

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(12 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

16

United States

4

Australia

4

Japan

3

Morocco

3

Lithuania

3

Israel

3

Singapore

3

China

3

EA

3

Canada

3

European Union

2

RS

2

Korea, Republic of

2

Brazil

2

Poland

2

Hungary

2

Croatia

2

Philippines

2

New Zealand

2

Denmark

1

Chile

1

Uruguay

1

Netherlands

1

Spain

1

Mexico

1

Slovenia

1

Argentina

1

Portugal

1

Colombia

1

Peru

1

Norway

1

Taiwan, Province of China

2. List of Rapivab drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6562861 BIOCRYST Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Dec, 2023

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391075 BIOCRYST Antiviral treatments
Feb, 2027

(4 years from now)

US8778997 BIOCRYST Antiviral treatments
May, 2027

(4 years from now)

Drugs and Companies using PERAMIVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adults

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

RAPIVAB family patents

12

United States

8

Korea, Republic of

4

Australia

4

Japan

3

Mexico

2

Brazil

2

EA

2

Canada

2

China

1

Hong Kong

1

South Africa

1

New Zealand

1

Malaysia

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in